Clinical trial

Canadian Study on the Association of Pessary With Progesterone

Name
13-159
Description
Prematurity is the leading cause of neonatal morbidity causing more than 1 million deaths worldwide per year. In 2012, a randomized controlled trial (RCT) testing "pessary" (silicone ring placed around the cervix) versus "no pessary" in patients with a short cervix showed a 4-fold reduction in the rate of spontaneous prematurity \<34 weeks of gestation and a reduction in perinatal morbidity and mortality. This result was not found in a subsequent RCT and another study on the subject had to be stopped in the face of slow recruitment. Currently, the obstetric scientific community believes that other RCTs are needed before using the pessary in the clinic as a therapeutic option to prevent prematurity in the presence of a short cervix. However, before starting a large RCT, it is important to test the feasibility of recruitment.
Trial arms
Trial start
2018-06-04
Estimated PCD
2022-10-06
Trial end
2022-10-06
Status
Completed
Treatment
Prometrium
Intravaginal use, off label, of Prometrium
Arms:
Intravaginal progesterone, Intravaginal progesterone and pessary
Other names:
Progesterone
Dr. Arabin, cerclage pessary perforated
A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
Arms:
Intravaginal progesterone and pessary
Other names:
Pessary
Size
79
Primary endpoint
Recruitment feasibility
Up to 24 weeks (18 to 42 weeks of gestation)
Eligibility criteria
Inclusion Criteria: * patient with a short cervix equal to or less than 25 mm by transvaginal ultrasound * gestational age between 18 (0/7) and 23 (6/7) weeks of gestation according to the results of the ultrasound of the first trimester, or by integrating the date of the last period * patients who were informed of the study and agreed to sign the consent form. Exclusion Criteria: * pregnancy with a fetus with a major congenital malformation - regular and painful uterine activity - history of preterm premature rupture of membranes (PPROM) - active vaginal bleeding - complete and incomplete placenta previa - cerclage of the cervix in place - antecedent of conisation - multiple gestation - ballooning of membranes outside the cervix into the vagina - allergy/intolerance or hypersensitivity to progesterone or any of its ingredients - chronic medical conditions that would interfere with study participation or evaluation of treatment - vaginal administration of another drug.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Randomized, controlled clinical trial.', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 79, 'type': 'ACTUAL'}}
Updated at
2023-04-06

1 organization

1 product

2 indications

Product
Prometrium
Indication
premature birth